DOCSLIB.ORG

Enkephalin After Peptidase Inhibition

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Enkephalin After Peptidase Inhibition J Pharmacol Sci 106, 295 – 300 (2008)2 Journal of Pharmacological Sciences ©2008 The Japanese Pharmacological Society Full Paper Great Increase in Antinociceptive Potency of [Leu5]Enkephalin After Peptidase Inhibition Kazuhito Akahori1, Kenya Kosaka1, Xing Lu Jin1, Yoshiharu Arai1, Masanobu Yoshikawa1, Hiroyuki Kobayashi1, and Tetsuo Oka1,* 1Department of Clinical Pharmacology, School of Medicine, Tokai University, Isehara 259-1143, Japan Received August 9, 2007; Accepted December 19, 2007 Abstract. Previous in vitro studies have shown that the degradation of [Leu5]enkephalin during incubation with cerebral membrane preparations is almost completely prevented by a mixture of three peptidase inhibitors: amastatin, captopril, and phosphoramidon. The present in vivo study shows that the inhibitory effect of [Leu5]enkephalin administered intra-third-ventricularly on the tail-flick response was increased more than 500-fold by the intra-third-ventricular pretreatment with the three peptidase inhibitors. The antinociceptive effect produced by the [Leu5]enkephalin in rats pretreated with any combination of two peptidase inhibitors was significantly smaller than that in rats pretreated with the three peptidase inhibitors, indicating that any residual single peptidase could inactivate significant amounts of the [Leu5]enkephalin. The present data, together with those obtained from previous studies, clearly demonstrate that amastatin-, captopril-, and phosphoramidon-sensitive enzymes play important roles in the inactivation of short endogenous opioid peptides, such as penta-, hepta-, and octa-peptides, administered intra-third-ventricularly to rats. Keywords: [Leu5]enkephalin, opioid peptide, antinociception, peptidase inhibitor Introduction in vitro isolated preparations, guinea-pig ileum, mouse vas deferens, and rat vas deferens. Results showed that It has been shown that when [Leu5]enkephalin (LE) is AsA played the greatest role in both guinea-pig ileum incubated with an ileal or striatal membrane fraction and rat vas deferens, while it played a similar role to for 60 min at 37°C in the presence of three peptidase either PsE or CsD in mouse vas deferens (2). inhibitors (PIs), amastatin (an aminopeptidase inhibitor), In addition to LE, our previous in vitro experiments captopril (a dipeptidyl carboxypeptidase inhibitor), and also revealed that the mixture of three PIs largely phosphoramidon (an endopeptidase-24.11 inhibitor), prevented the hydrolysis of endogenous opioid peptides approximately 98% of LE remains intact, while in the (EOPs), [Met5]enkephalin (ME), [Met5]enkephalin- absence of the PI, the LE is completely hydrolyzed after Arg6-Phe7 (ME-RF), [Met5]enkephalin-Arg6-Gly7-Leu8 incubation (1). This shows that LE is hydrolyzed, at least (ME-RGL), and dynorphin A (1-8) [dyn (1-8)] by in the cerebral membrane preparation, by only three cerebral membrane preparation (1, 3 – 5). Additionally, types of membrane-bound enzymes: amastatin-sensitive the close proximity of these enzymes to the opioid aminopeptidase(s) (AsA), captopril-sensitive dipeptidyl receptors in isolated preparations such as guinea-pig carboxypeptidase I (angiotensin I-converting enzyme, ileum (6), mouse vas deferens (7), and rat vas deferens kininase II, EC 3.4.15.1) (CsD), and phosphoramidon- (8), suggests that they act to terminate the physiological sensitive endopeptidase-24.11 (“enkephalinase”, EC action of these EOPs. 3.4.24.11) (PsE). The relative importance of the three Because the hydrolysis products of LE by either enzymes in the inactivation of LE was examined in three amastatin-, phosphoramidon-, or captopril-sensitive enzymes such as free Tyr and the [Tyr-Gly-Gly]-, [des- *Corresponding author. [email protected] Tyr]-, and [des-Tyr-Gly-Gly]-fragments are suggested Published online in J-STAGE doi: 10.1254/jphs.FP0071318 to have very low, if any, agonist activity at opioid 295 296 K Akahori et al receptors (9), the potency of the LE should be decreased was calculated for some experiments. by its hydrolysis with these three peptidases. In fact, the in vitro potency of LE in isolated preparations has In vivo apparent pA2 analysis been significantly increased by either amastatin, phos- Tail-flick latency of rats pretreated with the three phoramidon, or captopril (1, 2). PIs was measured before and 15 min after the i.t.v. In the present investigation, effects of the intra-third- administration of LE and converted to %MPE. The ventricular (i.t.v.) injection of three PIs were examined dose-effect curve of an agonist in each rat was on the antinociception induced by the i.t.v. administra- constructed by injecting the rat with two or three tion of LE. doses, such as 0.5, 1 and 2 nmol, with 48-h inter-injec- tion interval. Individual ED50 values were calculated by Materials and Methods least-squares regression of the data in the portion of the dose-effect curve spanning the 50% MPE. The mean Chemicals ED50 value was obtained from individual ED50 values. Captopril and naloxone hydrochloride were kindly Naloxone was given subcutaneously 5 min before the provided by Sankyo (Tokyo). LE, amastatin, and phos- i.t.v. administration of the agonist. Dose-ratio was phoramidon were purchased from Peptide Institute, Inc. calculated by dividing each ED50 value in the presence (Minoh). Chemicals were dissolved in saline. The stock of naloxone by the mean ED50 value in the absence of solution for all peptides used was prepared at concentra- naloxone. The pooled pA2 value was determined by tions of 0.1 – 10 mM in siliconized plastic tubes, entering all the dose-ratio values (12). maintained at −18°C, and then diluted to the desired concentration just before use. In vitro isolated preparations Male ICR-Jcl mice weighing 40 – 50 g and male Microinjection into the third cerebral ventricle Hartley guinea pig weighing 400 – 600 g were used for Male Wistar rats weighing 180 – 220 g were the study. The mouse vas deferens and the myenteric anesthetized with pentobarbital sodium (40 mg/kg, plexus longitudinal muscle strip of guinea-pig ileum intraperitoneally), mounted on a stereotaxic frame, and were set up for electrical stimulation as described implanted with stainless-steel injection cannulae previously (13). The percent inhibition of the stimulated (external diameter of 0.30 mm) 5 – 7 days prior to the muscle twitch produced by an opioid was plotted against day of the experiment. The lower end of the injection the log concentration of the opioid to estimate the IC50 cannula was aimed at the third cerebral ventricle (opioid concentration producing 50% inhibition of the (6.0 mm anterior from lambda and 7.8 mm ventral from twitch). When the effect of peptidase inhibitors on the the surface of the skull) according to the atlas of Paxinos IC50 value of an opioid peptide was studied, these and Watson (10). The injection cannula was attached were given 5 min before the administration of the to a motor-driven 50-µl microsyringe by polyethylene opioid peptide. The ratio of the potency and the tubing. Drugs were injected in volumes of 10 µl for percentage difference, shown in Table 1, were calculated 1 min. The distribution of the drug solution in the from the following formulas: ratio of potency = IC50 cerebroventricular system was verified by infusion of without peptidase inhibitor / IC50 with peptidase methylene blue dissolved in saline after the experiment. inhibitors, and % difference = [(IC50 without peptidase inhibitor − IC50 with peptidase inhibitors) / IC50 without Tail-flick response peptidase inhibitor] × 100. The antinociceptive effect of LE was measured by the tail immersion assay with 55°C as the nociceptive Statistical analyses stimulus (11). The latency to flick the tail from the All values are reported as the mean with S.E.M. of the 55°C water was measured before and 5, 10, 15, 30, data. A statistical analysis was conducted using 45, and 60 min after the opioid administration. The computer software (The SPSS 14.0.1; SPSS, Inc., latency to flick the tail before the administration was Chicago, IL, USA) for comparison across the experi- approximately 1 s (0.5 – 1.7 s). A cut-off time of 5 s was mental conditions. When a significant difference among used to prevent any injury to the tail. The percent of the groups of AUC data was obtained in the one-way maximal possible effect (MPE) for each animal at each analysis of variance (ANOVA), the Bonferroni’s time was calculated using the following formula: multiple comparison test or the Dunnett’s post-hoc test %MPE = [(test latency − baseline latency) / (5 − baseline was applied to define which group contributed to these latency)] × 100. The AUC (area under the curve) value differences. The statistical significance of percent for the antinociceptive action of an opioid on each rat differences between IC50 values of two adjacent groups Analgesia of [Leu5]Enkephalin 297 Table 1. The enhancing effects of the peptidase inhibitors (PIs) on the inhibitory potency of [Leu5]enkephalin in guinea-pig ileum (GPI) and mouse vas deferens (MVD) Preparations PIs n IC50 (nM) Ratio of potency %Difference GPI None 5 296 ± 56 1 82.3 ± 1.3** ACP 5 50.5 ± 8.9 5.79 ± 0.50 MVD None 4 10.5 ± 2.5 1 60.0 ± 5.0* ACP 4 3.83 ± 0.51 2.64 ± 0.38 The mixture of three PIs, amastatin (A), captopril (C), and phosphoramidon (P), at the final concentration of 1 µM each was given 5 min before the [Leu5]enkephalin administration. Values are the means ± S.E.M. of n experiments. *P<0.05, **P<0.01. shown in Table 1 was determined by the Wilcoxon smaller than that at the dose of 0.1 nmol in rats treated signed-rank test. The level of statistical significance with three PIs (Fig. 2). Thus, the antinociceptive effect was set at P<0.05. of LE administered i.t.v. on the tail-flick response was increased more than 500-fold by the i.t.v.
Load more

Recommended publications
  • Analytical Performance of an Immunoassay to Measure Proenkephalin ⁎ Leslie J
    Clinical Biochemistry xxx (xxxx) xxx–xxx Contents lists available at ScienceDirect Clinical Biochemistry journal homepage: www.elsevier.com/locate/clinbiochem Analytical performance of an immunoassay to measure proenkephalin ⁎ Leslie J. Donatoa, ,Jeffrey W. Meeusena, John C. Lieskea, Deborah Bergmannc, Andrea Sparwaßerc, Allan S. Jaffea,b a Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States b Division of Cardiology, Mayo Clinic, Rochester, MN 55905, United States c Sphingotec GmbH, Hennigsdorf, Germany ARTICLE INFO ABSTRACT Keywords: Background: Endogenous opioids, enkephalins, are known to increase with acute kidney injury. Since the mature Biomarkers pentapeptides are unstable, we evaluated the performance of an assay that measures proenkephalin 119–159 Proenkephalin (PENK), a stable peptide formed concomitantly with mature enkephalins. Enkephalin Methods: PENK assay performance was evaluated on two microtiterplate/chemiluminescence sandwich im- Pro-enkephalin munoassay formats that required 18 or 1 h incubation times. PENK concentration was measured in plasma from penKid healthy individuals to establish a reference interval and in patients with varied levels of kidney function and Assay validation comorbidities to assess the association with measured glomerular filtration rate (mGFR) using iothalamate clearance. Results: Assay performance characteristics in plasma were similar between the assay formats. Limit of quanti- tation was 26.0 pmol/L (CV = 20%) for the 1 h assay and 17.3 pmol/L (CV = 3%) for the 18 h assay. Measurable ranges were 26–1540 pmol/L (1 h assay) and 18–2300 pmol/L (18 h assay). PENK concentrations are stable in plasma stored ambient to 10 days, refrigerated to at least 15 days, and frozen to at least 90 days.
    [Show full text]
  • Antitumor Activity of Actinonin in Vitro and in Vivo
    Vol. 4, 171-176, January 1998 Clinical Cancer Research 171 Antitumor Activity of Actinonin in Vitro and in Vivo Yang Xu, Lawrence T. Lai, Janice L. Gabrilove, 8), mye!oid and monocytic cells, and most myeloblastic leuke- and David A. Scheinberg’ mias as well as on cells and tissues outside the hematopoietic system including fibroblasts, intestinal epithelium, renal tubular Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021 epithelium, and synaptic membranes of the central nervous system (I ). APN occurs as a homodimer, and the molecule is a 150-kDa, transmembrane glycoprotein with an intracellular ABSTRACT amino terminus (1). F23, an antihuman CD13/APN mAb, is able Actinonin, an antibiotic and CD13/aminopeptidase N to completely block the active site of the enzyme (9). (APN) inhibitor, has been shown to be cytotoxic to tumor Bestatin, a CD 1 3/APN inhibitor, was examined in preclin- cell lines in vitro. We investigated the antiproliferative ef- ical and clinical studies; bestatin could inhibit lymph node fects of actinonin on human and murine leukemia and lym- metastasis of P388 leukemia in mice (10) and was used in phoma cells. Actinonin inhibited growth of NB4 and HL6O clinical trials in malignant skin tumors (1 1), in head and neck human cell lines and AKR mouse leukemia cells in vitro with cancer (12), in esophageal cancer (13), and in gynecologic an IC50 of about 2-S g/ml. The inhibitory effect on CD13- tumors (14). High doses of bestatin resulted in the significant positive cells was not blocked by pretreatment with the inhibition of preexisting experimental and spontaneous metas- anti-CD13/APN monoclonal antibody F23, which binds with tasis in mice (15).
    [Show full text]
  • New Trends in the Development of Opioid Peptide Analogues As Advanced Remedies for Pain Relief
    Current Topics in Medicinal Chemistry 2004, 4, 19-38 19 New Trends in the Development of Opioid Peptide Analogues as Advanced Remedies for Pain Relief Luca Gentilucci* Dipartimento di Chimica “G. Ciamician”, via Selmi 2, Università degli Studi di Bologna, 40126- Bologna, Italy Abstract: The search for new peptides to be used as analgesics in place of morphine has been mainly directed to develop peptide analogues or peptidomimetics having higher biological stability and receptor selectivity. Indeed, most of the alkaloid opioid counterindications are due to the scarce stability and the contemporary activation of different receptor types. However, the development of several extremely stable and selective peptide ligands for the different opioid receptors, and the recent discovery of the m-receptor selective endomorphins, rendered this search less fundamental. In recent years, other opioid peptide properties have been investigated in the search for new pharmacological tools. The utility of a drug depends on its ability to reach appropriate receptors at the target tissue and to remain metabolically stable in order to produce the desired effect. This review deals with the recent investigations on peptide bioavailability, in particular barrier penetration and resistance against enzymatic degradation; with the development of peptides having activity at different receptors; with chimeric peptides, with propeptides, and with non-conventional peptides, lacking basic pharmacophoric features. Key Words. Opioid peptide analogues; opioid receptors; pain; antinociception; peptide stability; bioavailability. INTRODUCTION. OPIOID PEPTIDES, RECEPTORS, receptor interaction by structure-function studies of AND PAIN recombinant receptors and chimera receptors [7,8]. Experiments performed on mutant mice gave new The endogenous opioid peptides have been studied information about the mode of action of opioids, receptor extensively since their discovery aiming to develop effective heterogeneity and interactions [9].
    [Show full text]
  • Structural Basis for Multifunctional Roles of Mammalian Aminopeptidase N
    Structural basis for multifunctional roles of mammalian aminopeptidase N Lang Chen, Yi-Lun Lin, Guiqing Peng, and Fang Li1 Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455 Edited by Ralph S. Baric, University of North Carolina, Chapel Hill, NC, and accepted by the Editorial Board September 21, 2012 (received for review June 13, 2012) Mammalian aminopeptidase N (APN) plays multifunctional roles in sensation and mood regulation by catalyzing the metabolism of many physiological processes, including peptide metabolism, cell neuropeptides that process sensory information. One of these motility and adhesion, and coronavirus entry. Here we determined neuropeptides is enkephalin, which binds to opioid receptors and crystal structures of porcine APN at 1.85 Å resolution and its com- has pain-relief and mood-regulating effects (9). APN degrades plexes with a peptide substrate and a variety of inhibitors. APN is and shortens the in vivo life of enkephalin, and hence enhances a cell surface-anchored and seahorse-shaped zinc-aminopeptidase pain sensation and regulates mood. Second, APN is involved in that forms head-to-head dimers. Captured in a catalytically active blood pressure regulation. APN degrades vasoconstrictive peptide state, these structures of APN illustrate a detailed catalytic mech- angiotensin-III, causing vasodilation and lowered blood pressure anism for its aminopeptidase activity. The active site and peptide- (10). An endogenous APN inhibitor, substance P, blocks both binding channel of APN reside in cavities with wide openings, the enkephalin-dependent and angiotensin-dependent pathways allowing easy access to peptides. The cavities can potentially open (11, 12). Third, APN is overexpressed on the cell surfaces of up further to bind the exposed N terminus of proteins.
    [Show full text]
  • Nociceptin/Orphanin FQ (N/OFQ) Modulates Immunopathology and Airway Hyperresponsiveness Representing a Novel Target for the Treatment of Asthma
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by De Montfort University Open Research Archive British Journal of British Journal of Pharmacology (2016) 173 1286–1301 1286 BJP Pharmacology RESEARCH PAPER Nociceptin/orphanin FQ (N/OFQ) modulates immunopathology and airway hyperresponsiveness representing a novel target for the treatment of asthma Correspondence Professor David G Lambert, Department of Cardiovascular Sciences, University of Leicester, Division of Anaesthesia, Critical Care and Pain Management, Leicester Royal Infirmary, Leicester, UK. E-mail: [email protected] Received 22 May 2015; Revised 02 December 2015; Accepted 10 December 2015 Shailendra R Singh1,2, Nikol Sullo1,3, Maria Matteis3,GiuseppeSpaziano3, John McDonald1, Ruth Saunders2, Lucy Woodman2, Konrad Urbanek3, Antonella De Angelis3,RaffaeleDePalma6,RachidBerair2,Mitesh Pancholi2,VijayMistry2,FrancescoRossi3, Remo Guerrini5, Girolamo Calò4,BrunoD’Agostino3,ChristopherE Brightling2*andDavidGLambert1,* 1Department of Cardiovascular Sciences, University of Leicester, Division of Anaesthesia, Critical Care and Pain Management, Leicester Royal Infirmary, Leicester LE2 7LX, UK, 2Institute for Lung Health, Department of Infection, Immunity and Inflammation and Health Sciences, University of Leicester, Leicester, UK, 3Department of Experimental Medicine, Section of Pharmacology L Donatelli,, Second University of Naples, Naples, Italy, 4Department of Medical Sciences, Section of Pharmacology, University of Ferrara, Ferrara, Italy, 5Department
    [Show full text]
  • Product List Subcatalog Biochemica
    Product Article Name Package Product Article Name Package number Productsize Listnumber size Subcatalog Biochemica Take the pink Link! www. .com AppliChem gmbH AppliChem Scandinavia AppliChem Inc. Ottoweg 4 Lyngby Storcenter 66, Lejl. 1203 2814 Mary Avenue D-64291 Darmstadt DK-2800 Kongens Lyngby 63144 St. Louis Germany Denmark Missouri, USA Phone +49 6151 9357-0 Phone +45 39 64 46 66 Phone +1 314 968-3331 Fax +49 6151 9357-11 Fax +45 39 64 34 81 Fax +1 314 968-5006 eMail [email protected] eMail [email protected] eMail [email protected] www.applichem.com Article number Name Package Article number Name Package size size A2110,0005 A23187 5 mg A9541,0010 3-Acetyl-9-11-dehydro-beta-boswel- 10 mg lic acid HPLC grade A2110,0010 A23187 10 mg A5269,0020 6-O-Acetylacteoside HPLC grade 20 mg A7847,0005 A23187 calcium magnesium salt 5 mg BioChemica A5269,0050 6-O-Acetylacteoside HPLC grade 50 mg A1088,0001 ABTS® BioChemica 1 g A3753,0010 Acetyl-Coenzym A trilithium salt 10 mg BioChemica A1088,0005 ABTS® BioChemica 5 g ® A3753,0050 Acetyl-Coenzym A trilithium salt 50 mg A1088,0010 ABTS BioChemica 10 g BioChemica A7817,0020 Acacetin HPLC grade 20 mg A3753,0100 Acetyl-Coenzym A trilithium salt 100 mg A7817,0050 Acacetin HPLC grade 50 mg BioChemica A1060,0100 ACES Buffer grade 100 g A8502,0005 3-Acetyldeoxynivalenol 5 mg A1060,0250 ACES Buffer grade 250 g A7451,0001 N-Acetyl-D-galactosamine 1 g A1060,1000 ACES Buffer grade 1 kg A7451,0005 N-Acetyl-D-galactosamine 5 g A3986,0025 ACES Molecular biology grade 25 g A2554,0025 N-Acetyl-D-glucosamine
    [Show full text]
  • The Enhancing Effects of Amastatin, Phosphoramidon and Captopril on the Potency of [Met5]-Enkephalin in Rat Vas Deferens Suying
    The Enhancing Effects of Amastatin, Phosphoramidon and Captopril on the Potency of [Met5]-Enkephalin in Rat Vas Deferens Suying CUI", Midori KAJIWARA,Kaori ISHII, KazukoAOKI, Junshi SAKAMOTO,Teruhiko MATSUMIYAand Tetsuo OKA* Departmentof Pharmacology,School of Medicine,Tokai University, Isehara259-11, Japan AcceptedMay 29, 1986 Abstract-The enkephalin-inactivating enzymes in rat vas deferens were studied by using the relatively specific inhibitor of each enzyme. The results showed that the rat vas deferens, like the other three preparations, guinea-pig ileum, mouse vas deferens and striatal membranes of guinea-pig brain, which had been investigated previously, contained three distinct enkephalin-hydrolyzing peptidases. Additionally, the enkephalin-hydrolyzing aminopeptidase, endopeptidase-24.11 and peptidyl dipeptidase A in rat vas deferens were found to be inhibited maximally with 1 IN of amastatin, 1 iiM of phosphoramidon and 1 ,IM of captopril, respectively. In contrast to these three enzymes, both L-tyrosyl-L-tyrosine-sensitive dipeptidyl aminopeptidase and D-phenylalanine-sensitive carboxypeptidase were suggested not to be involved significantly in the inactivation of exogenously given enkephalin in rat vas deferens. The characteristics of the enkephalin-degradative enzymes in rat vas deferens were discussed in terms of their similarities to and differences from those in the other preparations. Three enzymes, both bestatin and peptidases, since enkephalin remains intact amastatin-sensitive aminopeptidase, both almost totally after
    [Show full text]
  • Discovery of Novel Opioid Medications
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Discovery of Novel Opioid Medications 147 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Discovery of Novel Opioid Medications Editors: Rao S. Rapaka, Ph.D. Heinz Sorer, Ph.D. NIDA Research Monograph 147 1995 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Discovery of Novel Opioid Medications” held on July 28-29, 1993. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • Biased Agonism of Endogenous Opioid Peptides at the Mu-Opioid Receptor Georgina L. Thompson, J. Robert Lane, Thomas Coudrat
    Molecular Pharmacology Fast Forward. Published on May 26, 2015 as DOI: 10.1124/mol.115.098848 This article has not been copyedited and formatted. The final version may differ from this version. MOL #99848 Biased agonism of endogenous opioid peptides at the mu-opioid receptor Georgina L. Thompson, J. Robert Lane, Thomas Coudrat, Patrick M. Sexton, Arthur Christopoulos and Meritxell Canals Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia (G.L.T., J.R.L., T.C., P.M.S., A.C., M.C.) Downloaded from Defence Science and Technology Organisation, Department of Defence, Fishermans Bend, VIC 3207, Australia (G.L.T.) molpharm.aspetjournals.org at ASPET Journals on September 24, 2021 1 Molecular Pharmacology Fast Forward. Published on May 26, 2015 as DOI: 10.1124/mol.115.098848 This article has not been copyedited and formatted. The final version may differ from this version. MOL #99848 Running title: Endogenous biased agonism at the mu-opioid receptor Georgina L. Thompson, J. Robert Lane, Thomas Coudrat, Patrick M. Sexton, Arthur Christopoulos* and Meritxell Canals* * Corresponding authors: Meritxell Canals and Arthur Christopoulos, Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Parkville, VIC 3052, Australia. Telephone: + 61-3-99039094. Email: [email protected], Downloaded from [email protected] molpharm.aspetjournals.org Page number: 38 Figure number: 6 Reference number: 69 at ASPET Journals on September 24, 2021 Abstract
    [Show full text]
  • Information to Users
    INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy. Higher quality 6" x 9" black and white photographic prints are available for any photographs or illustrations appearing in this copy for an additional charge. Contact UMI directly to order. University Microfilms International A Bell & Howell Information Company 300 North Zeeb Road. Ann Arbor. Ml 48106-1346 USA 313/761-4700 800/521-0600 Order Number 9201617 Metabolism of vasoactive peptides by aminopeptidase M Benter, Ibrahim Fadil, Ph.D. The Ohio State University, 1991 UMI 300 N. Zeeb RA Ann Arbor, MI 48106 METABOLISM OF VASOACTIVE PEPTIDES E« AMTNOPEPTIDASE M DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of the Ohio State University By Ibrahim Fadil Benter, B.S.
    [Show full text]
  • Neural Mechanism Underlying Acupuncture Analgesia Progress in Neurobiology
    Progress in Neurobiology 85 (2008) 355–375 Contents lists available at ScienceDirect Progress in Neurobiology journal homepage: www.elsevier.com/locate/pneurobio Neural mechanism underlying acupuncture analgesia Zhi-Qi Zhao * Institute of Neurobiology, Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Fudan University, Shanghai 200032, China ARTICLE INFO ABSTRACT Article history: Acupuncture has been accepted to effectively treat chronic pain by inserting needles into the specific Received 20 December 2007 ‘‘acupuncture points’’ (acupoints) on the patient’s body. During the last decades, our understanding of Received in revised form 19 March 2008 how the brain processes acupuncture analgesia has undergone considerable development. Acupuncture Accepted 30 May 2008 analgesia is manifested only when the intricate feeling (soreness, numbness, heaviness and distension) of acupuncture in patients occurs following acupuncture manipulation. Manual acupuncture (MA) is the Keywords: insertion of an acupuncture needle into acupoint followed by the twisting of the needle up and down by Acupuncture hand. In MA, all types of afferent fibers (Ab,Ad and C) are activated. In electrical acupuncture (EA), a Electrical acupuncture Acupuncture point stimulating current via the inserted needle is delivered to acupoints. Electrical current intense enough to Afferent fibers excite Ab- and part of Ad-fibers can induce an analgesic effect. Acupuncture signals ascend mainly Neural mechanisms through the spinal ventrolateral funiculus to the brain. Many brain nuclei composing a complicated network are involved in processing acupuncture analgesia, including the nucleus raphe magnus (NRM), periaqueductal grey (PAG), locus coeruleus, arcuate nucleus (Arc), preoptic area, nucleus submedius, habenular nucleus, accumbens nucleus, caudate nucleus, septal area, amygdale, etc.
    [Show full text]
  • DYNORPHIN-CONVERTING ENZYME in HUMAN CEREBROSPINAL a Negative Correlation Between Activity and Levels of Prodynorphin Derived Op
    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/308329883 Dynorphin-converting enzyme in human cerebrospinal fluid. A negative correlation between activity and levels of prodynorphin derived opioid peptides Data · September 2016 CITATIONS READS 0 30 6 authors, including: Claes Post Henning Værøy Linköping University Akershus universitetssykehus 174 PUBLICATIONS 5,425 CITATIONS 65 PUBLICATIONS 1,763 CITATIONS SEE PROFILE SEE PROFILE Fred Nyberg Uppsala University 467 PUBLICATIONS 13,047 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: The impact of opioid peptides in body fluids View project Frondoside A, anti cancer agent View project All content following this page was uploaded by Henning Værøy on 20 September 2016. The user has requested enhancement of the downloaded file. s155 DYNORPHIN-CONVERTING ENZYME IN HUMAN CEREBROSPINAL FLUID. A negative correlation between activity and levels of prodynorphin derived opioid peptides. Madeleine ThSmwall, Susanne Schwarzmayr, Bela Almay *, Claes Post **, Henning VaerCy *** and Fred Nyberg. Dept. of Pharmaceutical Biosciences, Division of Pharmacology, University of Uppsala, P.O. Box 591, S-751 24 UPPSALA, Sweden.* Dept. of Neurology, University of Ume~, S-801 87 UMEA, Sweden.** Astra Draeo AB P.O. Box 34, S-221 20 LUND, Sweden.*** Dept. of Psychiatry, Gjcvik Fylkessykehus, N-2800 GJI~VIK, Norway. In this work we have studied the dynorphin convertase (DCE) in cerebrospinal fluid (CSF) collected from patients with different states of chronic pain. The assessment of the enzyme activity was accompanied with measurements of the CSF level of prodynorphin derived opioid peptides. In CSF from patients with fibromyalgia the DCE activity was found to be significantly decreased as compared to that of control samples.
    [Show full text]